Dinaciclib

Dinaciclib

Legal status
Legal status	Investigational
Identifiers
IUPAC name (S)-3-(((3-Ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)pyridine 1-oxide
Synonyms	SCH-727965
CAS Number	779353-01-4
PubChem CID	46926350
IUPHAR/BPS	7379
ChemSpider	25027387
ChEMBL	CHEMBL2103840
PDB ligand	1QK (PDBe, RCSB PDB)
Chemical and physical data
Formula	C21H28N6O2
Molar mass	396.50 g·mol−1
3D model (Jmol)	Interactive image
SMILES CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO
InChI InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1 Key:PIMQWRZWLQKKBJ-SFHVURJKSA-N

Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs). It is being evaluated in clinical trials for various cancer indications.

Dinaciclib is being developed by Merck & Co. It was granted orphan drug status by the FDA in 2011.